New Systemic Options for Managing cSCC: A Care Team Forum
Program Overview
This is the first of a 2-part round-table discussion that brings together the expertise of a dermatologist, medical oncologist, and Mohs surgeon and pairs it with a first-hand account of how Jim, a cutaneous squamous cell carcinoma (cSCC) survivor, and his caregiver navigated the ups and downs of a rapidly-metastatic cSCC diagnosis and treatment labyrinth. In this activity, learners will explore pressing questions regarding the safety and efficacy of new systemic options for managing advanced cSCC not otherwise amenable to curative surgical strategies.
The intended audience for this activity is Mohs surgeons, medical oncologists, and dermatologists who manage patients with cutaneous squamous cell carcinoma (cSCC).
Educational Objectives
Upon completion of this activity, participants should be better able to:
Utilize novel and emerging agents to manage advanced cutaneous squamous cell carcinoma (cSCC) based on their efficacy and safety data and mechanisms of action
Incorporate shared decision making (SDM), quality of life assessment and management, and collaborative care for patients with cSCC to improve patient outcomes
Activity Faculty
Chrysalyne D. Schmults, MD, MSCE
Associate Professor, Dermatology
Harvard Medical School Director, Mohs and Dermatologic Surgery Center
Dana-Farber/Brigham and Women’s Cancer Center
Boston, MA
Omid Hamid, MD
Chief, Translational Research and Immunotherapy Director, Cutaneous Oncology
The Angeles Clinic and Research Institute
Los Angeles, CA
Anokhi Jambusaria, MD, MSCE, FAAD
Assistant Professor, Division of Dermatology
Department of Internal Medicine
The University of Texas
Austin Dell Medical School
Austin, TX